HCPCS Level II · Outpatient PPS (temporary codes)
C9081Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Terminated 12/31/2021
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About C9081
C9081 is an HCPCS Level II code in the C series (outpatient PPS (temporary codes)), describing idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.
It was added to HCPCS effective 10/01/2021, and its current record took effect 01/01/2022.
It was terminated on 12/31/2021 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Idecabtagene car pos t
- Date added
- 10/01/2021
- Action effective
- 01/01/2022
- Termination date
- 12/31/2021
- BETOS
- O1D
Related C90xx codes
Common questions about C9081
Is HCPCS C9081 still valid?
- No. C9081 was terminated on 12/31/2021.
Does Medicare cover C9081?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.